Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Testicular Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | University of Chicago | P2 | BB · 68 |
| Fludarabine | Case Comprehensive Cancer Center | P2 | BBB |
| Rituximab | Mayo Clinic | P2 | BBB |
| Cyclophosphamide | University of Chicago | P2 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Dexasone | Singapore General Hospital | P2 | BB |
| Romidepsin | Mayo Clinic | P2 | BB |
| Adriamycin | University of Chicago | P2 | BB |
+36 more in the Testicular Lymphoma cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in Testicular Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-testicular-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →